| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Mary Ann Cloyd is Director at EKSO, with reported holdings spanning 3 companies. Mary Ann Cloyd's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $896K at current prices.
Mary Ann Cloyd's largest disclosed position is in DMC as Director, worth about $896K.
Mary Ann Cloyd has 42 Form 4 filings on record from May 2019 to May 2026, across 3 companies: Director at Del Monte (DMC), 2026; Director at Ekso Bionics (EKSO), 2021–2025; Director at Fresh Del Monte Produce (FDP), 2019–2025.
The 55 reported transactions were 24 option or other derivative awards, 21 option exercises, 8 stock awards and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $91K.
The largest open-market sale was 1,689 shares of FDP at an average $27.20 on August 7, 2024, about $46K. Twelve months later FDP was up 32%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.